IP Library Granted Patent US 6,893,871
Granted Patent B2
US 6,893,871 · App. 10/744,508 · Granted May 17, 2005

Human ovarian mesothelial cells and methods of isolation and uses thereof

Assignee: Raven Biotechnologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,893,871
App. No.
10/744,508
Granted
May 17, 2005
Kind
B2
Abstract

The invention discloses a substantially pure population of human ovarian mesothelial cells and methods of isolating and culturing the ovarian mesothelial cells. By carefully manipulating the microenvironment of the ovarian mesothelial cells, multiple passages are attainable wherein the ovarian mesothelial cells are capable of becoming ovary surface epithelial cells or granulosa cells. In addition, several methods of use of human ovarian mesothelial cells are disclosed herein.

Claims (3)

1. A method of providing a source of immunogen to a heterologous recipient, comprising administering a plurality of ovarian mesothelial cells in an amount effective to induce an immune response in said recipient, wherein said ovarian mesothelial cells have a pluripotent capacity to differentiate into ovary surface epithelial cells or granulosa cells.

2. A method of generating human ovarian tissue models in non-human mammalian recipients, comprising administering a plurality of human ovarian mesothelial cells into said recipients, wherein said ovarian mesothelial cells are first maintained in basal nutrient and then administered at a location within said recipient, said location being able to support growth and differentiation of said ovarian mesothelial cells, and wherein said ovarian mesothelial cells have a pluripotent capacity to differentiate into ovary surface epithelial cells or granulosa cells.

3. A method of providing cell therapy to a recipient, comprising administering human ovarian mesothelial cells into said recipients, wherein said ovarian mesothelial cells are first grown in nutrient media and then administered at a location within said recipient, said location being able to support growth and differentiation of said ovarian mesothelial cells, and wherein said ovarian mesothelial cells have a pluripotent capacity to differentiate into ovary surface epithelial cells or granulosa cells.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2014
From: MACROGENICS WEST, INC.
To: MACROGENICS, INC.
Reel/Frame 034630/0402 →
SECURITY AGREEMENT Recorded Jan 12, 2011
From: DIADEXUS, INC. (FORMERLY VAXGEN, INC.)
To: RAVEN BIOTECHNOLOGIES, INC.
Reel/Frame 025622/0237 →
SECURITY AGREEMENT Recorded Jun 13, 2008
From: RAVEN BIOTECHNOLOGIES, INC.
To: VAXGEN, INC.
Reel/Frame 021096/0008 →
Continuity (3)
Division 1044517900 · May 23, 2003
Division 0954565900 · Apr 10, 2000
Related Publication 20040137614A1 · Jul 15, 2004